- Home
- MDGL vs DECK Comparison
MDGL vs DECK Comparison
Compare MDGL & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDGL | DECK |
|---|---|---|
| Founded | 2011 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 12.4B |
| IPO Year | 2005 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MDGL | DECK |
|---|---|---|
| Price | $499.71 | $79.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 27 |
| Target Price | ★ $682.11 | $120.41 |
| AVG Volume (30 Days) | 188.1K | ★ 2.8M |
| Earning Date | 11-03-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.90 |
| EPS | N/A | ★ 0.94 |
| Revenue | $180,133,000.00 | ★ $5,472,296,000.00 |
| Revenue This Year | $59.37 | $7.43 |
| Revenue Next Year | $39.35 | $7.23 |
| P/E Ratio | ★ N/A | $82.98 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $393.61 | $77.37 |
| 52 Week High | $615.00 | $122.29 |
Technical Indicators
Market Signals| Indicator | MDGL | DECK |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 36.22 |
| Support Level | $501.44 | $77.37 |
| Resistance Level | $543.75 | $83.00 |
| Average True Range (ATR) | 15.08 | 2.00 |
| MACD | -2.69 | 0.46 |
| Stochastic Oscillator | 18.82 | 16.77 |
Price Performance
Historical ComparisonAbout MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
About DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.